News | February 15, 2025
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Subscribe To Our Newsletter & Stay Updated
